AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle ...

Recommendation based on AMPLIFY Phase III trial which showed Calquencecombinations demonstrated statistically significant and clinically meaningfulimprovement in progression-free survival vs.

(Alliance News) - AstraZeneca PLC on Tuesday said Calquence plus chemoimmunotherapy has been approved in the European Union for previously untreated mantle cell lymphoma in adults.

The Committee for Medicinal Products for Human Use (CHMP) has recommended that a fixed-duration regimen of Calquence ...

(Alliance News) - AstraZeneca PLC on Tuesday said Calquence plus chemoimmunotherapy has been approved in the European Union for previously untreated mantle cell lymphoma in adults. The Cambridge ...

UK pharma major AstraZeneca (LSE: AZN) today revealed that its Calquence (acalabrutinib) in combination with bendamustine and ...